RxDoctor Payments Data

Maurice Weiss, MD

Cardiovascular Disease · Neptune, NJNPI 1659350882

Payments from drug & device makers

$12,431in general payments, 2019–2025

Across 924 payments — averaging $13.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$2K
  • Abbott$1K
  • AstraZeneca$1K
  • Johnson & Johnson$970
  • Amgen$777
  • E.r. Squibb & Sons, L.L.C.$614
  • plus $5K from 39 others

What the payments were for

  • Food & beverage$12,374100%
  • Education$570%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,431 in reported general payments places this provider in the 80th percentile of 1,006 cardiovascular disease providers in New Jersey.

See all cardiovascular disease providers in New Jersey

Medicare billing

Part B allowed, 2024
$1,333,833
Medicare patients
1,469
Services billed
11,393

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban310$361,512
EntrestoSacubitril/Valsartan170$214,134
FarxigaDapagliflozin Propanediol117$123,796
BrilintaTicagrelor154$109,891
XareltoRivaroxaban86$108,351
Repatha SureclickEvolocumab91$104,588
OzempicSemaglutide79$78,963
JardianceEmpagliflozin32$46,503
Praluent PenAlirocumab37$37,386
LivaloPitavastatin Calcium45$32,881
VerquvoVericiguat12$22,524
WegovySemaglutide15$21,048
Pitavastatin Calcium62$16,972
Coreg CrCarvedilol Phosphate14$16,369
Nebivolol Hcl236$15,254

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$380$361,512310 claims
AstraZenecaFarxiga, Brilinta$1,041$233,687271 claims
NovartisEntresto$2,450$214,134170 claims
Johnson & JohnsonXarelto$970$108,35186 claims
Novo NordiskOzempic, Wegovy$507$100,01194 claims
Boehringer IngelheimJardiance$356$46,50332 claims
Kowa Pharmaceuticals America, Inc.Livalo$375$32,88145 claims
MerckVerquvo$532$22,52412 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,006 cardiovascular disease providers in New Jersey.

Other cardiovascular disease in Neptune

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →